Journal of Cosmetic Dermatology

<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Melasma is a chronic refractory pigmentation disorder. Kligman triple (KT) formula is the gold standard. A dermocosmetic (DC) serum containing vitamin B3 and 2‐mercaptonicotinyl glycine has been developed for melasma. This study assessed the benefits of DC serum compared to KT in melasma.</jats:p></jats:sec><jats:sec><jats:title>Material and Methods</jats:title><jats:p>A randomized, single‐blind 6‐month study was conducted in women with melasma. Subjects were randomized to Group A (morning: serum; evening: cream, for 6 months) or to Group B (1st 3 months: morning: skin hydrating gel; evening: KT, followed by 3 months of DC routine regimen); all subjects applied a sunscreen with an SPF 50+ twice daily. Assessments included MASI, mMASI, IGA, skin hydration, radiance and fine wrinkles, tolerance, and quality of life (QoL) using MELASQOL.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Ninety‐one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (<jats:italic>p</jats:italic> &lt; 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (<jats:italic>p</jats:italic> &lt; 0.05) percentage reduction of MASI score, with no between‐group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (<jats:italic>p</jats:italic> &lt; 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Both DC routine and KT significantly improved melasma after 3 months of use. DC further improved melasma when replacing KT for 3 further months, with similar results when used alone for 6 months.</jats:p></jats:sec>

publication_history

received

accepted

published

Melasma, a Photoaging Disorder

Pigment Cell & Melanoma Research

Update on Melasma‐Part I: Pathogenesis

Dermatol Ther (Heidelb)

Melasma's Impact on Quality of Life

Journal of Drugs in Dermatology

A Global Survey of the Role of Ultraviolet Radiation and Hormonal Influences in the Development of Melasma

Journal of the European Academy of Dermatology and Venereology

Melasma: A Clinico‐Epidemiological Study of 312 Cases

Indian Journal of Dermatology

Intrinsic and Extrinsic Factors in Skin Ageing: A Review

International Journal of Cosmetic Science

Photoprotection: Current Developments and Controversies

Cutaneous Interaction With Visible Light: What Do We Know?

Journal of the American Academy of Dermatology

Effects of Visible Light on Mechanisms of Skin Photoaging

Photodermatology, Photoimmunology & Photomedicine

Faces of Cellular Senescence in Skin Aging

Mechanisms of Ageing and Development

Skin‐Aging Pigmentation: Who Is the Real Enemy?

Cells

Melasma: Updates and Perspectives

Experimental Dermatology

Melasma Treatment: A Systematic Review

Journal of Dermatological Treatment

Update on Melasma‐Part II: Treatment

An Update on the Safety of Hydroquinone

Archives of Dermatological Research

Clinical Efficacy of Cysteamine Application for Melasma: A Meta‐Analysis

Journal of Clinical Medicine

Reliability Assessment and Validation of the Melasma Area and Severity Index (MASI) and a New Modified MASI Scoring Method

Validation of a Melasma Quality of Life Questionnaire for Brazilian Portuguese Language: The MelasQoL‐BP Study and Improvement of QoL of Melasma Patients After Triple Combination Therapy

British Journal of Dermatology

Cysteamine Isobionic‐Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action

Topical Hydroquinone for Hyperpigmentation: A Narrative Review

Cureus

Exogenous Ochronosis Associated With Hydroquinone: A Systematic Review

International Journal of Dermatology

2‐Mercaptonicotinoyl Glycine Prevents UV‐Induced Skin Darkening and Delayed Tanning in Healthy Subjects: A Randomized Controlled Clinical Study

Mechanistic Insights Into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products

Antioxidants (Basel)

Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation

Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus

Melasma is a chronic refractory pigmentation disorder. Kligman triple (KT) formula is the gold standard. A dermocosmetic (DC) serum containing vitamin B3 and 2-mercaptonicotinyl glycine has been developed for melasma. This study assessed the benefits of DC serum compared to KT in melasma.
A randomized, single-blind 6-month study was conducted in women with melasma. Subjects were randomized to Group A (morning: serum; evening: cream, for 6 months) or to Group B (1st 3 months: morning: skin hydrating gel; evening: KT, followed by 3 months of DC routine regimen); all subjects applied a sunscreen with an SPF 50+ twice daily. Assessments included MASI, mMASI, IGA, skin hydration, radiance and fine wrinkles, tolerance, and quality of life (QoL) using MELASQOL.
Ninety-one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (p < 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (p < 0.05) percentage reduction of MASI score, with no between-group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (p < 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine.
Both DC routine and KT significantly improved melasma after 3 months of use. DC further improved melasma when replacing KT for 3 further months, with similar results when used alone for 6 months.

A Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use.

A Novel Dermocosmetic Routine Containing Vitamin <scp>B3</scp> and 2‐Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use

Papers